What is CJC-1295 No DAC used for?
CJC-1295 No DAC is used in preclinical and bench research on GHRH-receptor pharmacology — protocols typically study pulsatile growth hormone release that mirrors natural pituitary rhythms, often in combination with the selective GH secretagogue ipamorelin.
What the research literature says
CJC-1295 No DAC (modified GRF 1-29) is the short-acting GHRH-analogue variant designed for pulsatile GH release rather than the sustained receptor stimulation produced by the long-acting CJC-1295 DAC variant. The 30-minute plasma half-life supports daily or twice-daily dosing with each dose producing a discrete GH-release pulse from the pituitary.
The GHRH-receptor pharmacology framework is anchored by the Jetté CJC-1295 identification work (PMID 15817669) and the Teichman clinical-pharmacology work in healthy adults (PMID 16352683) — both characterised the DAC variant directly but inform the No DAC framework via shared receptor pharmacology. The Alba GHRH-knockout mouse model confirmed receptor-specificity (PMID 16822960). The Ionescu pulsatile-GH-secretion work examined whether pulsatile GH release persists during continuous GHRH stimulation, with implications for both variants (PMID 17018654).
Combined-research workflows pairing CJC-1295 No DAC with ipamorelin engage GHRH receptor + ghrelin receptor (GHSR-1a) on the same somatotroph cells simultaneously. The Ronin catalog offers this combination as the CJC-1295 + Ipamorelin Blend; standalone single-component vials are also available for independent dose control of each component.
Why this matters in research context
Researchers selecting CJC-1295 No DAC over the DAC variant are anchoring protocol design to pulsatile rather than sustained GH-axis pharmacology. The choice depends on whether the experimental question requires the natural-rhythm-mimicking pulsatile pattern (No DAC) or the sustained-elevation pharmacology (DAC). Most research-supply protocols favour the No DAC variant because the pulsatile pattern aligns better with physiological GH regulation.
Related compounds
- CJC-1295 No DAC 10mg — the compound covered by this answer
- CJC-1295 + Ipamorelin Blend — single-vial combination
- Ipamorelin 10mg — complementary GH-axis compound
Related research questions
- What is the half-life of CJC-1295 No DAC?
- What is the difference between CJC-1295 with and without DAC?
- Can CJC-1295 be stacked with ipamorelin?
References
- Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146(7):3052-3058. [PMID 15817669]
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. [PMID 16352683]
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91(12):4792-4797. [PMID 17018654]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. CJC-1295 No DAC is sold strictly as a research-grade reagent for laboratory and bench research applications.